Budesonide–Glycopyrronium–Formoterol Fumarate Dihydrate in Uncontrolled Asthma: KALOS and LOGOS

12 Feb 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

These findings show that BGF improves lung function and reduces severe exacerbation rates in a broad population with asthma inadequately controlled despite medium-dose or high-dose ICS–LABA use.
Given that these findings were observed regardless of recent exacerbation history, BGF could benefit individuals with inadequately controlled asthma without requiring a recent episode of acute deterioration on ICS–LABA before escalation.

Clinical Editorial

The Lancet Respiratory Medicine published a clinical update in Critical Care on 12 Feb 2026.

The item focuses on Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.

Review the original article for the full source wording and details.